Literature DB >> 18307172

Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines.

Emmanouil D Karagiannis1, Aleksander S Popel.   

Abstract

Angiogenesis is tightly regulated by numerous endogenous pro- and anti-angiogenic proteins and peptides. Among these are the CXC chemokines, a set of multifunctional peptides. CXC chemokines containing the ELR motif act as pro-angiogenic agents by regulating both endothelial cell proliferation and migration. Here we show that a set of six 22-24-amino acid peptides derived from the pro-angiogenic ELR-containing CXC chemokines exhibit notable anti-proliferative and anti-migratory activity in vitro; we call these peptides chemokinostatins. The ability of the identified peptides to inhibit the basic components of angiogenesis even though they are derived from pro-angiogenic proteins contributes towards the understanding of the diverse role of the CXC chemokine family in angiogenesis. 2008 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  2008        PMID: 18307172     DOI: 10.1002/jcb.21712

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts.

Authors:  Jacob E Koskimaki; Emmanouil D Karagiannis; Elena V Rosca; Farhad Vesuna; Paul T Winnard; Venu Raman; Zaver M Bhujwalla; Aleksander S Popel
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

2.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

3.  Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity.

Authors:  Corban G Rivera; Elena V Rosca; Niranjan B Pandey; Jacob E Koskimaki; Joel S Bader; Aleksander S Popel
Journal:  J Med Chem       Date:  2011-09-13       Impact factor: 7.446

4.  Angiogenesis-associated crosstalk between collagens, CXC chemokines, and thrombospondin domain-containing proteins.

Authors:  Corban G Rivera; Joel S Bader; Aleksander S Popel
Journal:  Ann Biomed Eng       Date:  2011-05-18       Impact factor: 3.934

5.  Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.

Authors:  Elena Victoria Rosca; Bachchu Lal; Jacob E Koskimaki; Aleksander S Popel; John Laterra
Journal:  Anticancer Drugs       Date:  2012-08       Impact factor: 2.248

Review 6.  Anti-angiogenic peptides for cancer therapeutics.

Authors:  Elena V Rosca; Jacob E Koskimaki; Corban G Rivera; Niranjan B Pandey; Amir P Tamiz; Aleksander S Popel
Journal:  Curr Pharm Biotechnol       Date:  2011-08       Impact factor: 2.837

7.  Effect of mini-tyrosyl-tRNA synthetase on ischemic angiogenesis, leukocyte recruitment, and vascular permeability.

Authors:  Gang Cheng; Hua Zhang; Xianglei Yang; Eleni Tzima; Karla L Ewalt; Paul Schimmel; James E Faber
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-08-27       Impact factor: 3.619

Review 8.  Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.

Authors:  Julio Valdivia-Silva; Jaciel Medina-Tamayo; Eduardo A Garcia-Zepeda
Journal:  Int J Mol Sci       Date:  2015-06-08       Impact factor: 5.923

9.  Cancer treatment using peptides: current therapies and future prospects.

Authors:  Jyothi Thundimadathil
Journal:  J Amino Acids       Date:  2012-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.